Evidence map›Paper›PMID 38008447›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Multiple Gastric Neuroendocrine Tumors Associated with Long-term Use of a Proton Pump Inhibitor and a Potassium-competitive Acid Blocker.

Soichiro Nagao, Yohei Yabuuchi, Kosuke Tanaka, Yoshiki Morihisa, Takuya Kobayashi, Shinsuke Akiyama, Gensho Tanke, Masaya Wada, Shuko Morita, Satoko Inoue and 3 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Long-term use of potassium-competitive acid blockers and proton pump inhibitors and the risk of metachronous gastric cancer after H. pylori eradication: a multicenter cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Soichiro NagaoDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Yohei YabuuchiDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Kosuke TanakaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Yoshiki MorihisaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Takuya KobayashiDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Shinsuke AkiyamaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Gensho TankeDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Masaya WadaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Shuko MoritaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Satoko InoueDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Chung HobyungDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Daisuke YamashitaDepartment of Pathology, Kobe City Medical Center General Hospital, Japan.
Tetsuro InokumaDepartment of Gastroenterology, Kobe City Medical Center General Hospital, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 52-year-old man who had been using a proton pump inhibitor (PPI) and a potassium-competitive acid blocker (P-CAB) for 14 years underwent esophagogastroduodenoscopy and was found to have three neuroendocrine tumors (NETs) in the gastric body. Following detailed examinations, parietal cell dysfunction was excluded, and the NETs did not meet the criteria for the Rindi classification types I-III. The lesions were ultimately considered to be associated with the long-term use of the PPI and P-CAB. We performed endoscopic submucosal dissection of the lesions, with no recurrence or new lesions noted after discontinuation of the PPI and P-CAB.

Indexed as

Neuroendocrine TumorsProton Pump InhibitorsStomach NeoplasmsEndoscopy, Digestive SystemHumansMaleMiddle AgedProton Pump Inhibitorshypergastrinemianeuroendocrine tumorpotassium-competitive acid blockerproton pump inhibitor

Identifiers

PMID38008447
PMCPMC11309866
OpenAlexW4389033816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.